

Form PTO-1449 (modified)

Atty. Docket No.

OSTS:003USD2

Serial No.

09/879,445

List of Patents and Publications for Applicant's

## INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Applicant

Gregory R. Mundy

Wolfgang E. Gallwitz

Filing Date:

June 11, 2001

Group:

1642

U.S. Patent Documents

See Page 1

Foreign Patent Documents

See Page 1

Other Art

See Page 1

## U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.

## Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No

## Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
ATH	C26	Mori <i>et al.</i> , "Urinary excretion of parathyroid hormone-related protein in patients with adult T-cell leukemia and other hematologic disorders," <i>Rinsho Ketsueki</i> , 33(9):1158-65, 1992 (in Japanese).
ATH	C27	Ohoishi <i>et al.</i> , "Common acute lymphoblastic leukemia preceded by hypercalcemia in an infant," <i>Acta Paediatrica Japonica</i> , 38:549-552, 1996.
ATH	C28	Sakakibara <i>et al.</i> , "Hypercalcemia associated with all-trans-retinoic acid in the treatment of acute promyelocytic leukemia," <i>Leukemia Research</i> , 17(5):441-443, 1993.
ATH	C29	Nagasawa and Okawa, "All-trans retinoic acid induced hypercalcemia in a patient with acute promyelocytic leukemia: its relation to increased PTH-rP," <i>International Journal of Hematology</i> , 59:143-144, 1994.
ATH	C30	Vlasveld <i>et al.</i> , "Parathyroid hormone-related protein (PTH-rP)-associated hypercalcemia in a patient with an atypical chronic lymphocytic leukemia," <i>The Netherlands Journal of Medicine</i> , 54:21-26, 1999.

25525310.1

EXAMINER:

*Annelle H. H. H.*

DATE CONSIDERED:

6/15/2005

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)